RxDoctor Payments Data

Christopher Gans, MD

Cardiovascular Disease · Ann Arbor, MINPI 1790986644

Payments from drug & device makers

$80,101in general payments, 2019–2025

Across 60 payments — averaging $1335.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$37K
  • Novartis$26K
  • Boehringer Ingelheim$12K
  • AstraZeneca$5K
  • Abbott$377
  • Siemens Medical Solutions USA, Inc.$32
  • plus $19 from 1 others

What the payments were for

  • Speaking & faculty fees$30,20082%
  • Travel & lodging$5,26014%
  • Food & beverage$1,4744%

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,101 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$123,764
Medicare patients
1,155
Services billed
2,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$52,071
EntrestoSacubitril/Valsartan39$43,550
JardianceEmpagliflozin43$39,478
XareltoRivaroxaban15$15,095
Repatha SureclickEvolocumab20$13,092
Bisoprolol Fumarate50$1,218
Atorvastatin Calcium64$941
Metoprolol Succinate55$940
Rosuvastatin Calcium33$854
Spironolactone43$513
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$443
Torsemide29$402
Spironolactone-HctzSpironolact/Hydrochlorothiazid11$305
Chlorthalidone19$296
Carvedilol25$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36,505$52,07146 claims
NovartisEntresto$25,710$43,55039 claims
Boehringer IngelheimJardiance$12,210$39,47843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →